39 results
P
patients with cancers
I/C
F-NLR scoring system, high F-NLR score vs. low F-NLR score
O
overall survival (OS) and disease-free survival (DFS)/progression-free survival (PFS)
P
bladder cancer (BC) patients
I/C
18 F-FDG PET/CT, clinical response and nonresponse
O
tumor response to neoadjuvant chemotherapy
P
thyroid cancer (TCa) patients
I/C
F-18 fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT), ultrasonography (US)
O
detection of cervical lymph node (LN) metastasis
P
patients with vertebral compression fractures
I/C
F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT), differentiation of benign and malignant vertebral compression fractures
O
diagnostic performance, sensitivity, specificity, positive likelihood ratio, negative likelihood ratio
P
gynecological cancer
I/C
18 F-FDG PET, management of patients with recurrent gynecological cancers
O
changes in management
P
Asian people living with HIV
I/C
switching to bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF), staying on baseline regimens
O
maintained 100% virological suppression at week 48 with no treatment-emergent drug resistance and safety profiles comparable to those seen in people who stayed on baseline regimens
P
children
I/C
calcium phosphate (CaP) derivatives, no-intervention/placebo or Fluoride (F) use alone
O
caries preventive and tooth-remineralizing effect
P
373
I/C
Deep learning algorithms, Manual assessment
O
Accuracy, Precision, Recall, F-score, Dice coefficient
P
Yu X, Xu R, Zhang Z, Yang Y, Deng F
I/C
extra-short implants (≤ 6 mm), longer implants (≥ 8 mm)
O
bone augmentation
P
144 consecutive patients
I/C
first-line DA and SOFIA 6 F Plus catheter for LVOS, rescue stent-retriever
O
successful recanalization (mTICI 2b-3) rate of 75.7%, global rate for functional independence (90-day mRS 0-2) was 40.3%, mTICI 2b-3 rate was 71.6%, overall mTICI2b-3 rate after DA and rescue therapy was 88.9%, pooled estimate of 45.6% for functional independence, mortality within 90 days of 19%, rate of 5.8% of symptomatic intracranial hemorrhage